Finasteride Tablet, Film Coated
Product Images NDC 50268-314

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 50268-314). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

314 15 5mg

Finasteride Tablets, USP 5 mg film-coated tablets in a unit dose package with 50 tablets (5 x 10) by AvPAK. The label includes prescription-only designation, storage instructions, and warnings about use by women and children. Manufactured by AvKARE in Pulaski, TN.*

FDA Label Image

Figure1.jpg (Figure1)

A line graph showing the mean change from baseline over four years comparing Finasteride 5 mg oral tablets to placebo. The y-axis represents the mean change with standard error bars, and the x-axis tracks the timeline from baseline through year 4, illustrating a greater decrease in the measured parameter for Finasteride compared to placebo.*

FDA Label Image

Figure2.jpg (Figure2)

A line graph titled 'Figure 2 Percent of Patients Having Surgery for BPH, Including TURP' comparing Finasteride and Placebo groups over 48 months. The y-axis shows percent of patients, and the x-axis shows observation time in months. The graph includes two lines tracking cumulative surgery rates, with Finasteride showing a lower percentage over time compared to placebo. Below the graph, tables provide the number of events, cumulative events, and number at risk per year for each group.*

FDA Label Image

Figure3.jpg (Figure3)

A line graph showing mean percent change from baseline with standard error over four years for placebo and finasteride groups. The X-axis represents time points (Baseline, Year 1 to Year 4), and the Y-axis represents mean percent change. Two lines indicate different trends for placebo and finasteride, with group sample sizes indicated below the X-axis at each time point.*

FDA Label Image

Figure4.jpg (Figure4)

A line graph showing the percentage of events over years from randomization (0 to 5.5 years) for four groups: Placebo, Finasteride, Doxazosin, and Combination. The graph uses different symbols for each group, indicating event rates increasing over time, with Placebo having the highest and Combination the lowest percentage of events.*

FDA Label Image

Structure.jpg (Structure)

Chemical structure of Finasteride, a steroidal 5-alpha-reductase inhibitor, showing rings and functional groups including an amide and ketone, consistent with its molecular formula.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.